We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
WARF Signs License Agreement with Pfizer for Human Embryonic Stem Cells
News

WARF Signs License Agreement with Pfizer for Human Embryonic Stem Cells

WARF Signs License Agreement with Pfizer for Human Embryonic Stem Cells
News

WARF Signs License Agreement with Pfizer for Human Embryonic Stem Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WARF Signs License Agreement with Pfizer for Human Embryonic Stem Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pfizer, Inc and the Wisconsin Alumni Research Foundation (WARF) announced that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.

The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery. Securing appropriate licenses, in an area as broad moving as regenerative medicine, helps ensure efficient utilization of the many existing discoveries and inventions in this field and allows for the efficient transfer of information for development of future inventions.

"Our license with WARF provides us with information and materials that will allow us to use their cell lines to explore a whole new range of therapies," said Ruth McKernan, PhD, chief scientific officer of Pfizer Regenerative Medicine. "Stem cells can be used to create specialized human tissue. Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."

"Pfizer's stem-cell R&D goal is three fold: to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and, most importantly, to move towards cell therapy," said McKernan. "The benefit to public health could be tremendous as we pursue our discoveries to advance the treatment of debilitating diseases."

"We are pleased to enter into this licensing agreement with Pfizer," said Carl E. Gulbrandsen, managing director of WARF. "Pfizer's access to this key intellectual property may have far-reaching benefits for both public health and Wisconsin's growing biotechnology industry."

As advances in health care help people live longer, the need for new medicines to keep people healthy continues to grow. Pfizer researchers and scientists are working to discover and develop new ways to treat and prevent life-threatening and debilitating illnesses, as well as to improve wellness and quality of life.
Advertisement